Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males
Key facts
- Who runs it
- National Cheng-Kung University Hospital
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- Phase
- Phase 4
- People taking part
- 661 people, planned
- Started
- 9 Jul 2024
- Expected to end
- 31 Jul 2032
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Drug: Bismuth Subcitrate 120 MG Oral Tablet
- Esomeprazole 40mg
- Metronidazole 250 MG
- Tetracycline Pill
- Record updated
- 7 November 2024
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patients who are > 18 years
- H. pylori infection confirmed by histology of a gastric biopsy, a positive rapid urease test, or a positive 13C-urea breath test
Who cannot take part
- Previous allergic reactions to any drugs in the bismuth quadruple therapy
- History of H. pylori eradication
- Severe comorbidities
- Pregnant or breastfeeding women
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Helicobacter pylori eradication can reduce the risk of gastric cancer and decrease the recurrence of ulcers. However, in recent years, the increasing antibiotic resistance of Helicobacter pylori has reduced the efficacy of clarithromycin-based triple therapy to below 80%. The recent studies, including real-world data and a clinical trial, have consistently found that females have poorer eradication rate of Helicobacter pylori as compared with males. In previous clinical trial, investigators discovered that the efficacy of a 10-day bismuth quadruple therapy was not inferior to a 14-day bismuth quadruple therapy. However, it remains to be investigated whether the 10-day bismuth quadruple therapy is still non-inferior to the 14-day regimen in females.
Read full original descriptionShow less
This project continues the clinical trial to investigate whether the efficacy of the 10-day bismuth quadruple therapy in females is inferior to that in males and whether the 14-day bismuth quadruple therapy is superior to the 10-day regimen in females. The ultimate goal is to establish that male patients can use the 10-day bismuth quadruple therapy with fewer side effects and without compromising efficacy as compared with the 14-day regimen; while female patients are recommended to use the 14-day bismuth quadruple therapy as it would be more effective than the 10-day regimen.
Considering sex in research is becoming increasingly important, as females have more antibiotic-resistant Helicobacter pylori infection than males. The bismuth quadruple therapy can overcome most resistance issues. Researching and comparing the difference in the efficacy of bismuth quadruple therapy for Helicobacter pylori eradication between females and males are of significant clinical importance and align with current research trends.
The 3 groups in the trial
- The 10-day bismuth-based quadruple therapy group for femalesExisting treatment, for comparison
The female patients receive a 10-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Fuliclin 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.
Treatment: Drug: Bismuth Subcitrate 120 MG Oral Tablet, Esomeprazole 40mg, Metronidazole 250 MG, and Tetracycline Pill
- The 14-day bismuth-based quadruple therapy group for femalesExisting treatment, for comparison
The female patients receive a 14-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Fuliclin 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.
Treatment: Drug: Bismuth Subcitrate 120 MG Oral Tablet, Esomeprazole 40mg, Metronidazole 250 MG, and Tetracycline Pill
- The 10-day bismuth-based quadruple therapy group for malesExisting treatment, for comparison
The male patients receive a 10-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Fuliclin 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.
Treatment: Drug: Bismuth Subcitrate 120 MG Oral Tablet, Esomeprazole 40mg, Metronidazole 250 MG, and Tetracycline Pill
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Optimal Treatment Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Female Patients and Comparison of the Efficacy with That of Male Patients
- Criteria questions
- Built from NCT06509139, who can take part
- Record updated
- 7 November 2024